United Therapeutics Co. (NASDAQ:UTHR) Shares Bought by Milestone Asset Management LLC

Milestone Asset Management LLC grew its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 56.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 2,874 shares of the biotechnology company’s stock after purchasing an additional 1,037 shares during the quarter. Milestone Asset Management LLC’s holdings in United Therapeutics were worth $1,014,000 as of its most recent filing with the SEC.

A number of other hedge funds have also modified their holdings of the stock. Pacer Advisors Inc. grew its holdings in shares of United Therapeutics by 5.5% in the 4th quarter. Pacer Advisors Inc. now owns 597,634 shares of the biotechnology company’s stock worth $210,869,000 after acquiring an additional 30,931 shares during the last quarter. Center For Asset Management LLC increased its position in shares of United Therapeutics by 4.5% in the fourth quarter. Center For Asset Management LLC now owns 1,686 shares of the biotechnology company’s stock worth $595,000 after acquiring an additional 73 shares in the last quarter. KBC Group NV raised its holdings in shares of United Therapeutics by 6.2% during the fourth quarter. KBC Group NV now owns 123,055 shares of the biotechnology company’s stock valued at $43,418,000 after acquiring an additional 7,169 shares during the period. Blue Trust Inc. lifted its position in shares of United Therapeutics by 24.2% in the 4th quarter. Blue Trust Inc. now owns 1,745 shares of the biotechnology company’s stock valued at $625,000 after acquiring an additional 340 shares in the last quarter. Finally, Kingswood Wealth Advisors LLC acquired a new position in United Therapeutics in the 4th quarter worth approximately $225,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently issued reports on UTHR shares. HC Wainwright increased their target price on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a report on Thursday, October 31st. The Goldman Sachs Group upped their target price on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a report on Friday, November 1st. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 16th. TD Cowen upped their price target on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Finally, Oppenheimer upped their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $378.36.

United Therapeutics Price Performance

UTHR stock opened at $372.75 on Thursday. United Therapeutics Co. has a 52-week low of $208.62 and a 52-week high of $417.82. The company has a 50-day moving average of $365.77 and a two-hundred day moving average of $356.81. The stock has a market capitalization of $16.64 billion, a price-to-earnings ratio of 16.37, a price-to-earnings-growth ratio of 0.95 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating the consensus estimate of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $748.90 million during the quarter, compared to analysts’ expectations of $722.62 million. During the same quarter last year, the company earned $5.38 earnings per share. The firm’s revenue was up 22.9% on a year-over-year basis. Equities analysts expect that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

Insider Activity at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $370.71, for a total transaction of $3,707,100.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares in the company, valued at $955,319.67. This trade represents a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Nilda Mesa sold 224 shares of the firm’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $412.28, for a total transaction of $92,350.72. Following the transaction, the director now owns 5,783 shares of the company’s stock, valued at approximately $2,384,215.24. This represents a 3.73 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 149,048 shares of company stock worth $56,142,199. Company insiders own 11.90% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.